Top 10 Pharma Industries in Bangalore to Know in 2026

Bengaluru's pharma base leans toward biologics and contract research, development and manufacturing: seven of the nine companies profiled below work there. Every entry is checked against a filing, its own site or a regulator's document.

Why Bengaluru matters to pharma manufacturing and research

For sourcing, quality and business-development teams, Bengaluru's weight is not in volume generics. It is in biologics, in contract research, development and manufacturing organizations (CRDMOs) that take a molecule from discovery to commercial supply, and in formulation plants that hold approvals from regulators in the United States, the United Kingdom and the World Health Organization (WHO). If your next outsourcing decision involves a biologic, a toxicology package or a regulated-market generic, the sites below are worth knowing.

The work sits in a handful of industrial belts on the city's southern and north-western edges. On Hosur Road, Electronic City holds Biocon's headquarters. Further south, Bommasandra and the Jigani Link Road hold Syngene, Anthem's first unit and several Micro Labs plants. To the north-west, Peenya holds Eurofins Advinus, and Yeshwantpur holds Jubilant Biosys.

Two regulators oversee this base. Karnataka's Drugs Control Department is the state licensing authority that grants manufacturing licences. The Central Drugs Standard Control Organisation (CDSCO), India's national drug regulator, runs an office in the same Palace Road building. Both are covered in the regulator section below. For why the city became a biotech base in the first place, see Why Is Bangalore A Pharma And Biotech Hotspot?

How this list was built. Each company appears because a filing, the company's own site or a regulator's document places a manufacturing, research and development (R&D) or laboratory operation in Bengaluru Urban or Bengaluru Rural district. Franchise marketers, distributors, online pharmacies, sales offices and global capability centres are not listed. Inclusion is editorial and never paid. For the national picture, see our guide to pharma companies in India and India's 20 largest pharmaceutical companies.

Pharma companies in Bangalore

The nine companies below are listed alphabetically, not ranked. They span biologics makers, contract research and manufacturing organizations, preclinical and discovery CROs, and formulation and API producers. A Type line on each entry lets you scan by business model.

1. Anthem Biosciences

Est.: 2006, Bengaluru

Bengaluru operation: Unit I, No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bengaluru 560099

Type: CRDMO and specialty ingredients

Listed: NSE (ANTHEM), BSE (544449)

Revenue from operations, FY26 (April 2025–March 2026): ₹21,243 million (consolidated, audited)

Anthem was incorporated in Bangalore on 13 June 2006 and describes itself as a CRDMO with integrated new chemical entity (NCE) and new biological entity (NBE) capabilities, serving emerging biotech and large pharmaceutical companies. Its FY26 results release reports revenue up 15.2% from ₹18,446 million, and profit after tax of ₹5,918 million. CRDMO work brought in ₹17,727 million; specialty ingredients, ₹3,516 million.

Its July 2026 investor presentation lists three units: Unit I at Bommasandra, and Units II and III at Harohalli Industrial Area, Phase II, in the district Karnataka renamed Bengaluru South on 23 May 2025 (formerly Ramanagara). Group capacity is 425 kilolitres (KL) of custom synthesis and 142 KL of fermentation.

For qualification, note which unit will run your process. Despite the name, Bengaluru South is a separate district from Bengaluru Urban, so the Harohalli units carry a different district address on licences and audit reports.

Official site: anthembio.com [VERIFY domain] · Checked October 2026

2. Biocon Limited

Est.: 1978, Karnataka

Headquarters: 20th KM, Hosur Road, Electronic City, Bengaluru 560100

Bengaluru operation: Biologics manufacturing and R&D; a second Bengaluru footprint makes peptides, highly potent APIs (HPAPIs), fermentation APIs, oral solid doses and injectables

Type: Biologics / biosimilars, with generics and APIs

Listed: NSE (BIOCON), BSE (532523)

Revenue from operations, FY26: ₹16,927 crore (consolidated, as reported in the company's Q4 FY26 fact sheet)

Biocon was incorporated in Karnataka in 1978, as its corporate identity number on a February 2024 BSE filing shows. Its Q4 FY26 fact sheet splits FY26 revenue into biosimilars (₹10,431 crore), generics (₹3,168 crore) and CRDMO services through Syngene (₹3,739 crore).

The group's February 2026 investor presentation places biologics manufacturing and R&D in Bengaluru, alongside a second Bengaluru footprint for peptides, HPAPIs, fermentation APIs, oral solid doses and injectables. Other sites are in Visakhapatnam, Hyderabad, Chennai (R&D), Johor in Malaysia (insulins) and Cranbury, New Jersey.

The structure is changing. The same presentation says Biocon holds about 98% of Biocon Biologics and has in-principle board approval to buy the rest, consolidating the biosimilars business fully. It also holds 52.4% of Syngene. Supplier files that name a Biocon Biologics entity should be checked against the current legal entity.

Official site: biocon.com · Checked October 2026

3. Eurofins Advinus

Acquired by Eurofins: 2017, from the Tata Group

Bengaluru operation: Plots 21 & 22, Phase II, Peenya Industrial Area, Bengaluru 560058

Type: Preclinical CRO (toxicology, DMPK, chemistry)

Certification: Good Laboratory Practice (GLP) certificate GLP/C-257/2026, valid 9 January 2026 to 8 January 2029

Eurofins Scientific announced its agreement to acquire Advinus Therapeutics from the Tata Group on 26 July 2017. At the time, the business ran one Bangalore facility of 20,000 square metres with more than 300 staff, offering safety assessment, drug metabolism and pharmacokinetics (DMPK), chemistry, manufacturing and controls (CMC) services, and analytical R&D.

The Peenya site supports IND-enabling preclinical toxicology, chemical process development and long-term non-clinical toxicology, including carcinogenicity studies, according to Eurofins' India locations page, which also lists AAALAC accreditation for animal care. Its GLP certificate, issued on 23 February 2026 by India's National GLP Compliance Monitoring Authority (NGCMA), covers human and veterinary pharmaceuticals, agrochemicals, industrial chemicals, cosmetics, and food and feed additives.

The certificate is issued to Eurofins Advinus Agrosciences Services India Private Limited. Sponsors should confirm that the legal entity on the certificate matches the one in their study contract.

Official site: eurofins.com · Checked October 2026

4. Jubilant Biosys

Headquarters and Bengaluru operation: No. 96, Industrial Suburb, 2nd Stage, Yeshwantpur, Bengaluru 560022

Type: Drug discovery CRO

Parent: Jubilant Pharmova; Jubilant Biosys itself is not listed

Jubilant Biosys is the Indian drug discovery subsidiary of Jubilant Pharmova, which lists the Yeshwantpur address on its worldwide locations page. A second Jubilant Biosys site is in Noida, Uttar Pradesh.

The company calls its Bengaluru site an Integrated Drug Discovery Center. A November 2019 company release described services across biology, DMPK, toxicology, medicinal chemistry, and process R&D with GMP scale-up to Phase II, and more than 75 integrated discovery programmes in oncology, metabolic disorders, pain and inflammation, the central nervous system and rare diseases. The same release announced a 10-acre plot in Devanahalli Industrial Park, near the airport, for a new discovery site.

The 2019 release is the latest company document found on the Devanahalli site. Anyone scoping a discovery partnership should ask which Bengaluru site would host the work.

Official site: jubilantbiosys.com · Checked October 2026

5. Kemwell Biopharma

Headquarters: Bengaluru

Bengaluru operation: Biologics campus with drug-substance production, process development, analytical testing and commercial fill-finish

Type: Biologics CDMO

Listed: Not listed

Kemwell describes itself as a biologics contract development and manufacturing organization (CDMO) with "more than 45 years of manufacturing excellence". Its services run from cell-line development and process development to drug substance and sterile drug product, across monoclonal, bispecific and trispecific antibodies, recombinant proteins, biosimilars and cell therapy.

In a release dated 27 October 2025, Kemwell said its Bengaluru drug-product facility had completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI), following a technology transfer from Cipla. The company says the site is now cleared to manufacture and test injectables for the U.S. market. The same release gives over 5,000 litres of installed upstream capacity, in single-use and stainless-steel bioreactors, and fill-finish lines for liquid and lyophilized vials and isolator-based prefilled syringes.

The inspection outcome above is the company's own statement. A sponsor relying on it should ask for the FDA's Establishment Inspection Report (EIR) and confirm the site's street address, which Kemwell's release does not give.

Official site: kemwellbiopharma.com [VERIFY domain] · Checked October 2026

6. Micro Labs Limited

Headquarters: No. 31, Race Course Road, Bengaluru 560001

Bengaluru operations: Plants at Bommasandra (API; domestic formulations; regulated-market sterile products), Veerasandra, Peenya and Kumbalgodu

Type: Formulations and APIs

Listed: Not listed

Micro Labs says it runs 14 plants, and its manufacturing plants page places several in and around Bengaluru. At Bommasandra, an API plant makes active ingredients and intermediates; a domestic wing makes cephalosporin tablets, capsules, dry suspensions and injectables; and a regulated-market site makes sterile eye drops and liquid injectables, which the company says the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved in November 2010. Veerasandra makes beta-lactam solid orals and, per the company, holds UK MHRA, Health Canada and South African approvals.

The Kumbalgodu plant (Plot 15/A, 2nd Phase, Kumbalgodu Industrial Area) makes anti-tuberculosis tablets. WHO inspected it for prequalification from 18 to 21 February 2025 and, in its public inspection report, considered it "to be operating at an acceptable level of compliance with WHO GMP Guidelines".

Micro Labs is privately held, so there is no audited revenue to report. For institutional buyers, the WHO report is the most useful primary document on any Micro Labs Bengaluru site.

Official site: microlabsltd.com · Checked October 2026

7. OneSource Specialty Pharma

Corporate office: Star 1, opposite IIM Bangalore, Bilekahalli, Bannerghatta Road, Bengaluru 560076 (registered office: Vashi, Navi Mumbai)

Bengaluru operation: Flagship manufacturing facility in Bengaluru, which the company describes as U.S. FDA-approved; its releases do not give the street address

Type: CDMO (drug-device combinations, biologics, soft gelatin capsules, sterile injectables)

Listed: NSE (ONESOURCE), BSE (544292)

Revenue, Q1 FY27 (April–June 2026): ₹4,490 million, up 37% year on year (company release)

OneSource is a contract development and manufacturing organization (CDMO) with five manufacturing facilities, according to its results release of 24 July 2026. Its work spans drug-device combinations, including pens and cartridges for GLP-1 products such as semaglutide, tirzepatide and liraglutide; biologics drug substance and drug product; soft gelatin capsules; and sterile injectables.

In a release dated 29 April 2026, OneSource said its partner Dr. Reddy's Laboratories had received a Health Canada Notice of Compliance for semaglutide injection, with OneSource providing scale-up and manufacturing support. The July release says EU GMP and Australian TGA GMP approvals were received across two sites, without naming which ones.

OneSource's exchange filings give the same registered office in Vashi, Navi Mumbai, as Strides Pharma Science (No. 8). Sourcing teams should confirm which company holds the licence for a given product and which of OneSource's five sites makes it. (Inference.)

Official site: onesourcecdmo.com [VERIFY domain] · Checked October 2026

8. Strides Pharma Science

Est.: 1990

Headquarters: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru (registered office: Vashi, Navi Mumbai)

Bengaluru operation: Two manufacturing facilities, which the company calls KRSG and SEML

Type: Formulations (regulated-market generics)

Listed: NSE (STAR), BSE (532531)

Revenue from operations, FY26: ₹48,587 million (consolidated, as stated in the company's results release)

Strides makes generic medicines for more than 100 countries, with regulated markets in the United States, the United Kingdom, Canada, Australia, New Zealand and the Nordics. Its FY26 results release, filed on 18 May 2026, reports revenue up 6.4% from ₹45,653 million and reported profit after tax from continuing operations of ₹5,745 million.

The company's fact sheet lists seven manufacturing facilities: KRSG and SEML in Bengaluru, Alathur (Chennai), Puducherry, Chestnut Ridge (United States), Nairobi (Kenya) and Milan (Italy). It says four are FDA-approved and the company holds 208 abbreviated new drug application (ANDA) approvals, but it does not say which sites hold which approvals.

If you are qualifying a Strides product, ask which of the seven sites makes it and for that site's current regulatory status. The fact sheet's group-level approval count does not answer either question.

Official site: strides.com · Checked October 2026

9. Syngene International

Est.: 1993, Bengaluru

Headquarters: Biocon SEZ, Biocon Park, Plots 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099

Bengaluru operation: 90-acre headquarters campus with discovery, development and biologics manufacturing

Type: CRDMO

Listed: NSE (SYNGENE) · Subsidiary of Biocon (52.4%, per Biocon's February 2026 presentation)

Revenue from operations, FY26: ₹37,387 million (consolidated, audited)

Syngene was established in 1993 and calls itself "an operationally independent publicly listed subsidiary of Biocon Limited" in its Q4 FY26 investor presentation. It had 8,373 employees on 31 March 2026, including 5,778 scientists. Its audited FY26 results, filed on 29 April 2026, show consolidated profit of ₹3,167 million.

The Bengaluru campus holds most of Syngene's capabilities, including discovery, development and biologics manufacturing. Outside the city it has commercial API manufacturing in Mangaluru, an R&D centre in Hyderabad's Genome Valley, and a biologics site in Baltimore in the United States. The company says its facilities are approved by the FDA, the European Medicines Agency (EMA), the UK Veterinary Medicines Directorate, Health Canada and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and that it hosted 85 client and regulator audits in FY26.

Syngene's registered office sits on the Biocon Park campus, as its Annual Report 2026 shows, but it is a separate listed company. Contracts and quality agreements should name Syngene International Limited, not Biocon.

Official site: syngeneintl.com · Checked October 2026

Also in Bengaluru: one more company to know

One more listed drugmaker has its registered office in the Bommasandra industrial belt, though its filings stop short of naming a plant there.

10. Bal Pharma Limited

Registered office: Plot 21 & 22, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099

Corporate office: 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru 560052

Type: Pharmaceuticals (the company reports a single segment)

Listed: NSE (BALPHARMA)

Not yet confirmed: whether manufacturing takes place at the Bommasandra address

Bal Pharma's exchange filings of 11 February and 29 May 2026 give its registered office in Bommasandra Industrial Area and its corporate office on Palace Road, and report one business segment, pharmaceuticals. Neither filing names a manufacturing plant. Buyers should ask the company for the licensed site address behind any product before qualifying it. (Inference.)

Official site: balpharma.com [VERIFY domain] · Checked October 2026

Who checks their work

Every company above works under the same two regulators. The manufacturing licence on file for a Bengaluru plant is issued by Karnataka's Drugs Control Department. For biologics makers such as Biocon, Kemwell and Syngene, the central regulator joins that licensing inspection, because CDSCO takes part in licensing for biotech and biosimilar units. Both offices work from the same building on Palace Road, and the next section sets out what each does.

Regulators in Bengaluru

Neither office is a company, so neither counts toward the entries above.

Karnataka State Drugs Control Department

Status: State licensing authority for drugs under the Drugs and Cosmetics Act, 1940

Address: Palace Road, Bengaluru 560001

In India, state drugs controllers are the licensing authority for drug manufacture and sale. CDSCO's own South Zone disclosure describes them as "the Licensing Authority under the Act", with CDSCO's zonal offices set up to coordinate with them on uniform enforcement. Karnataka's department is listed at Palace Road in CDSCO's directory of state drugs controllers. For a Bengaluru plant, the manufacturing licence on file is issued here.

CDSCO office, Bengaluru

Status: Central Drugs Standard Control Organisation office for Karnataka, opened on 1 September 2009

Address: 2nd Floor, Office of the Drugs Controller for the State of Karnataka, Palace Road, Bengaluru 560001

CDSCO's Bengaluru page gives the address above, and its South Zone disclosure records the office's start date of 1 September 2009 and its jurisdiction over Karnataka. The same disclosure describes the joint work zonal offices do with state authorities: inspections to grant or renew licences for large-volume parenteral (LVP) units, vaccines and sera, blood banks, and biotech and biosimilar units, and for WHO-format Certificates of Pharmaceutical Product (COPP). For the biologics makers above, licensing inspections are therefore joint state and central inspections.

CDSCO also runs a port office at Kempegowda International Airport, which controls drug, cosmetic and medical device imports and exports and issues No Objection Certificates (NOCs) to customs.

What this means for sourcing and regulatory teams

Bengaluru's companies change shape faster than the lists written about them. Biocon has moved to take full ownership of Biocon Biologics, and the district holding two of Anthem's three units was renamed in May 2025 without either plant moving. Before qualifying a supplier here, confirm the current legal entity, its parent and the district on its licence.

The second lesson is that approvals and certificates are dated, and the burden of checking the date sits with the buyer. Eurofins Advinus holds a GLP certificate valid to 8 January 2029; Micro Labs' Kumbalgodu plant passed a WHO inspection in February 2025; Kemwell reports an FDA pre-approval inspection in 2025. Each of those is a point in time. Record the date you checked it, and ask for the regulator's own document rather than the company's summary.

Finally, group-level claims do not qualify a site. Strides and Syngene both publish approval counts for the whole company, not for each plant. The question that matters is which site makes your product, and what that site's own record shows. Our Ghaziabad guide applies the same test to a very different city.

This guide grows only as entries are confirmed. Companies with a manufacturing, R&D or laboratory operation in Bengaluru Urban or Bengaluru Rural district can ask to be considered through the contact page.

Frequently asked questions

How many pharma companies does this guide list for Bangalore?

Nine companies with a manufacturing, R&D or laboratory operation in Bengaluru: Anthem Biosciences, Biocon, Eurofins Advinus, Jubilant Biosys, Kemwell Biopharma, Micro Labs, OneSource Specialty Pharma, Strides Pharma Science and Syngene International. A tenth, Bal Pharma, is listed separately. Each is confirmed against a filing, the company's own site or a regulator's document.

What kinds of pharma industries operate in Bengaluru?

The companies in this guide cover biologics and biosimilars (Biocon), contract research, development and manufacturing (Anthem, Syngene), biologics and drug-device contract manufacturing (Kemwell, OneSource), preclinical and discovery research (Eurofins Advinus, Jubilant Biosys) and formulations and APIs (Micro Labs, Strides).

Where are Bengaluru's pharma plants and labs located?

Biocon is in Electronic City on Hosur Road. Syngene, Anthem's Unit I and several Micro Labs plants are in the Bommasandra industrial area. Eurofins Advinus is in Peenya, Jubilant Biosys in Yeshwantpur, and Micro Labs also runs plants at Veerasandra, Peenya and Kumbalgodu.

Which drug regulators have offices in Bengaluru?

Karnataka's Drugs Control Department, the state licensing authority, and an office of the Central Drugs Standard Control Organisation (CDSCO). Both are on Palace Road. CDSCO also runs a port office at Kempegowda International Airport for drug imports and exports.

Why are franchise companies and multinational offices not listed, and can my company be added?

Many Bangalore lists include sales offices, capability centres and franchise marketers. This guide lists only sites where medicines are made, developed or tested, confirmed by a primary document, and inclusion is never paid. A company with such an operation in Bengaluru Urban or Bengaluru Rural district can apply through the contact page; the desk checks every submission against a primary document before adding it.